The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption - Wikidata - awgldk - TriplyDB

The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption

The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption

http://www.wikidata.org/entity/Q36824388

about

Viral markers for HIV cure trials: are we getting any closer?Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers Lessons from acute HIV infection.Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days.Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy.HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA.HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART.Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.International AIDS Society global scientific strategy: towards an HIV cure 2016.A highly reproducible quantitative viral outgrowth assay for the measurement of the replication-competent latent HIV-1 reservoir A Systematic Review and Narrative Synthesis of Interventions for Parental Human Immunodeficiency Virus Disclosure.Measuring the Size of the Latent Human Immunodeficiency Virus Reservoir: The Present and Future of Evaluating Eradication Strategies.Clinical and public health implications of acute and early HIV detection and treatment: a scoping review."We Need to Deploy Them Very Thoughtfully and Carefully": Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States-A Qualitative Inquiry.Persistent HIV-1 replication during antiretroviral therapy.Update and New Directions in Therapeutics for Neurological Complications of HIV Infections.The Alphabet Soup of HIV Reservoir Markers.CROI 2017: Basic Science Review.Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication.Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy.Peripheral blood lymphocyte HIV DNA levels correlate with HIV associated neurocognitive disorders in Nigeria.Highlights from the Conference on Retroviruses and Opportunistic Infections 2016: 22-25 February 2016, Boston, Massachusetts, USA.Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations.A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study.Pegylated IFN-α-induced NK cell activation is associated with HIV-1 DNA decline in ART-treated HIV-1/HCV co-infected patients.What do we measure when we measure cell-associated HIV RNA.Blood biomarkers of expressed and inducible HIV-1.Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption.A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.Immune Interventions to Eliminate the HIV Reservoir.Decay of HIV DNA in the Reservoir and the Impact of Short Treatment Interruption in Kenyan Infants.Latent HIV dynamics and implications for sustained viral suppression in the absence of antiretroviral therapy.Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy.EFFECT OF SHORT-TERM ART INTERRUPTION ON LEVELS OF INTEGRATED HIV DNA.Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.

P2860

Q26740038-476F32FD-47BB-4CBC-BCB6-36F045081CF3 Q27312050-17FE935E-6246-4DEC-A845-783F4315FB7E Q30490195-93C1EFCA-FA30-47A4-8E2D-590F287ED0A7 Q31123548-601D2F03-5118-42E6-A239-2182FD4E0ABE Q33585386-70402F78-7EA1-4DBB-8200-FA347AD61AE8 Q33693987-93B1BB84-0052-43BD-A860-9C99512AE7B0 Q34531858-10964379-BD7B-4756-93C5-4F7A1EC4481B Q36734972-A7A17BDB-62A4-4C10-9F30-AE6F994262EB Q37309464-0ABFCA2A-E1A9-4873-9DC8-3FD1BAD2EC82 Q37624842-A3EA385C-784B-4393-AD9F-66499F7BF718 Q37661770-36FF9A83-E3A2-4A59-B015-67C538814824 Q37663180-ACA27A87-D42B-4D9E-9B52-C77F5EA01C7F Q38639742-810B6D68-29EA-4E6A-8826-5B1C413AB545 Q38682297-9F6737DA-3031-4C8F-A552-57178AE71363 Q38686953-6EDE7A4C-77F6-485F-B54F-25E354469A8F Q38754318-2FDAFEA3-D07C-4767-8234-D035428762A2 Q38808266-DDC53E5C-97C0-485E-9450-C554B5D214C1 Q38887659-82C8A7ED-6403-42C0-A0D5-B27F7920823A Q39237000-4CC0339B-B212-4CE1-A64C-580B39416413 Q39362290-2E2EFF7F-FB9C-4FAD-8C4A-2D4F58F02E7D Q40120304-5569223B-A88A-4DDD-B61D-C1C62A6C704D Q40203692-3EE71B81-B76F-45D4-AFFC-6143E3EE7B71 Q40250340-1E52691E-5FD3-4077-AFDB-2B6FBC9BD9B1 Q40315607-89BEA9F7-65CC-45AE-9B91-A011E7552A52 Q40591692-45DFC175-20D8-4EAC-BCB4-72D34E7282A4 Q41918728-7C700EDC-B118-4005-9B56-F9F961F5A04C Q41929341-C46A2348-0DED-4825-A390-2EE654DB7149 Q42365537-BFE2871F-19DF-4A9C-931A-1A46C078891B Q47096232-AE9DD95A-5906-424F-AED6-5132588F707A Q47258805-033968D0-B8AE-4513-8462-E174ED285268 Q47548192-DA64DDA9-67DD-4BC1-96F5-DA4E632A93BF Q47553595-4FFBA3AE-1ABF-4DC7-B848-6D7B58DB1DCF Q47553711-14229810-7C2A-4868-B48D-35415BB55464 Q47568717-E9C40CE3-F104-4597-BC88-D438C707BD31 Q47600062-3C9BEFEC-D140-46B7-9B4E-649E4EDC6FD4 Q49888173-3BF1901C-9EEC-4495-B825-8908A658369B Q52313087-C003BAF3-735D-4383-960C-FCB1BFB90BAA Q52597179-CEE530D1-C28F-4033-9B3B-FF0C5A45B8EA Q52624999-CC829F50-0377-4557-9753-636D32C853F9 Q52657975-B29B6E58-351B-4527-9D63-773898A3B7EF

P2860

The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption

http://www.wikidata.org/entity/Q36824388

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The size of the expressed HIV ...... d after treatment interruption

@en

type

label

The size of the expressed HIV ...... d after treatment interruption

@en

prefLabel

The size of the expressed HIV ...... d after treatment interruption

@en

P1433

Q36824388-4ADF5DF5-259D-4CFE-ABF2-945047DBB618

P1476

Q36824388-2050E252-ED96-4426-ADA0-78D53A4F383D

P2093

Q36824388-067AAB10-9406-44E4-BC9D-01D9E014CE03

Q36824388-4269413B-0F1B-446D-8351-26263F297AA9

Q36824388-5EDA98C0-B676-4DE8-8534-43DB81422277

Q36824388-7D7FFDC5-D770-424D-8FFC-22EAEA4A2128

Q36824388-876C828B-791E-4298-BDC0-4D05A24FFDDE

Q36824388-A9A2BC62-26E4-4154-88A9-CD9113D8C94B

Q36824388-BF049A7B-28E3-42D6-BAE0-261460356453

Q36824388-CE212ED9-91DC-4895-A1DC-296973FF6FF1

Q36824388-E01B2070-6B4A-42EB-A11B-4A9769AF2A12

Q36824388-E5B54822-E699-4D8C-ACC2-2D7306B6C66D

P2860

Q36824388-005D8491-1C40-442F-B05A-86EF3AAD6BC2

Q36824388-02302112-A9AA-4B75-9692-58DDD93E7997

Q36824388-05816AF4-85D3-4D04-BFFA-ACB91D43A3D6

Q36824388-06930E3D-5946-43ED-BEB8-3A23D6EC7EF9

Q36824388-06B77778-7E6C-4C99-8276-70B203E9C123

Q36824388-100B1341-4192-4136-BA56-C01CB1D984C3

Q36824388-16C0FEE9-F594-40E1-9E96-9FB6B940FA0A

Q36824388-17E6C353-8357-4FF6-B903-5E4882CE104B

Q36824388-1B4E0000-BB87-48AB-8805-21CD68235C99

Q36824388-1C3EC746-996A-4E64-BDC3-B4EC360011EF

P304

Q36824388-709DE816-5FDC-4BE3-A17A-C7404E77C487

P31

Q36824388-C787DE06-3B8C-4289-AC99-2AE566FF339F

P356

Q36824388-31B526A3-BD7F-499D-80AA-44819E9AB947

P407

Q36824388-41629276-F8E1-4F5C-834C-F4D3602A963D

P433

Q36824388-4431EF85-8D49-43B3-B48E-007003690B0A

P478

Q36824388-6F1B8166-2A12-44DE-9AA7-6C1DD6D51B49

P577

Q36824388-5355E1E3-C626-423B-A1F2-444D8A3C0CF7

P698

Q36824388-839B09CD-5BC8-4520-8567-14788C8AF110

P932

Q36824388-DAE3F182-15B1-479F-9C36-0F51FDADB309

P356

QAD.0000000000000953

P1433

P1476

The size of the expressed HIV ...... d after treatment interruption

@en

P2093

Behzad Etemad

http://www.w3.org/2001/XMLSchema#string

Daniel R Kuritzkes

http://www.w3.org/2001/XMLSchema#string

Evgenia Aga

http://www.w3.org/2001/XMLSchema#string

Hayat Ahmed

http://www.w3.org/2001/XMLSchema#string

John W Mellors

http://www.w3.org/2001/XMLSchema#string

Jonathan Z Li

http://www.w3.org/2001/XMLSchema#string

Michael M Lederman

http://www.w3.org/2001/XMLSchema#string

Michael Para

http://www.w3.org/2001/XMLSchema#string

Rajesh T Gandhi

http://www.w3.org/2001/XMLSchema#string

Ronald J Bosch

http://www.w3.org/2001/XMLSchema#string

P2860

Latent reservoirs of HIV: obstacles to the eradication of virus

Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy

Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.

Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial.

Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs.

P304

343-353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0000000000000953

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26588174

http://www.w3.org/2001/XMLSchema#string

P932

4840470

http://www.w3.org/2001/XMLSchema#string